The 4 most recent market catalysts affecting $CRI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On Carter's with Outperform Rating, Announces Price Target of $40
BMO Capital's initiation of coverage on Carter's (CRI) with an 'Outperform' rating and a $40 price target is a positive development for the company. Analyst coverage, especially wi…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 85
Carter's, shares are trading lower after the company reported Q2 financial results and issued Q3 sales guidance below estimates. Also, the company issued FY26 sales guidance below estimates.
The headline signals a significant negative corporate catalyst for Carter's (CRI). The combination of underperforming Q2 results and downward revisions to both near-term (Q3) and l…
Jul 31, 2026
Corporate Catalyst
Neutral
Impact 95
Carter's Sees Q3 Sales $2.956B-$2.985B vs $798.520M Est
Carter's (CRI) has released Q3 sales guidance that is dramatically higher than current analyst estimates. The company projects sales between $2.956 billion and $2.985 billion, whic…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 85
Carter's Q2 Adj. EPS $0.26 Beats $0.06 Estimate, Sales $615.000M Beat $605.675M Estimate
Carter's (CRI) announced Q2 adjusted EPS of $0.26, significantly exceeding the analyst consensus of $0.06, representing a 333.33% beat and a 52.94% increase year-over-year. Sales a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.